Mandaviya calls for collaboration to eliminate vector borne diseases

PHARMAP 2022 concludes with productive networking of pharma leaders

The Congress was held on June, 20-21, 2022 in Berlin, Germany

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects

CPC Scientific announces new California peptide API manufacturing facility

The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity

Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients

Nippon Express launches new transport service using environmental-friendly isothermal packaging

Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport

Saint-Gobain Life Sciences expands manufacturing facility in Japan

The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry

FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer

Acceptance based on results from the phase 3 KEYNOTE-091 trial

Nippon Express launches ultra-low temperature-controlled service for pharma industry

Nippon Express has provided a pharmaceutical distribution platform with strict temperature control in two ranges -- 2 C to 8 C

Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus

Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.